AbCellera Biologics Inc. reported total revenue of $23.0 million for the nine months ended September 30, 2026, a decrease from $30.3 million in the prior year period. The company recorded a net loss of $151.3 million for the first nine months of 2026, driven by significant research and development expenses of $136.2 million as it advances its internal drug candidate pipeline, including ABCL635.
AbCellera reported Q3 2026 financial results with revenue of $10.6 million and a net loss of $40.8 million. The company highlighted positive Phase 2 data for its ABCL635 program and a $200 million capital raise that increased total liquidity to approximately $890 million.
Term
Q3 2026
“This was a transformative quarter for AbCellera, highlighted by strong clinical execution and balance sheet expansion. Positive top-line Phase 2 results for ABCL635 demonstrated an efficacy and tolerability profile that has potential to redefine the treatment of hot flashes.”
Carl Hansen, Ph.D., founder and CEO of AbCellera
“On the strength of this data, we raised $200 million, bringing our available liquidity to approximately $900 million. Together with the top-line Phase 1 readout of ABCL575 and the addition of three new pipeline programs, ABCL992, ABCL385, and ABCL646, we have delivered on all corporate priorities for 2026.”